Latest filings (excl ownership)
10-Q
2024 Q1
Quarterly report
14 May 24
DEFA14A
Additional proxy soliciting materials
9 May 24
8-K
ACELYRIN, INC. Provides Business Update and Highlights Key Upcoming Milestones
9 May 24
ARS
2023 FY
Annual report to shareholders
22 Apr 24
DEFA14A
Additional proxy soliciting materials
22 Apr 24
DEF 14A
Definitive proxy
22 Apr 24
S-8
Registration of securities for employees
28 Mar 24
10-K
2023 FY
Annual report
28 Mar 24
8-K
ACELYRIN, INC. Reports Full Year 2023 Financial Results and Recent Highlights
28 Mar 24
8-K
Rapid improvements demonstrated for proptosis, clinical activity scores, and diplopia versus placebo with a favorable safety profile
20 Mar 24
8-K
ACELYRIN, INC. Announces Positive Top-line Results from Its Global Phase 2b/3 Clinical Trial of Izokibep in Psoriatic Arthritis
11 Mar 24
8-K
Departure of Directors or Certain Officers
20 Dec 23
8-K
ACELYRIN, INC. Provides Update on Izokibep Clinical Development Program
27 Nov 23
10-Q
2023 Q3
Quarterly report
9 Nov 23
8-K
ACELYRIN, INC. Reports Third Quarter 2023 Financial Results and Recent Highlights
7 Nov 23
8-K
Departure of Directors or Certain Officers
21 Aug 23
8-K
ACELYRIN, INC. Reports Second Quarter 2023 Financial Results and Recent Highlights
14 Aug 23
10-Q
2023 Q2
Quarterly report
14 Aug 23
8-K
Departure of Directors or Certain Officers
2 Aug 23
8-K
ACELYRIN, INC. Reports First Quarter 2023 Financial Results and Recent Highlights
15 Jun 23
10-Q
2023 Q1
Quarterly report
15 Jun 23
8-K
ACELYRIN, INC. Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
9 May 23
S-8
Registration of securities for employees
8 May 23
424B4
Prospectus supplement with pricing info
5 May 23
EFFECT
Notice of effectiveness
5 May 23
S-1MEF
Registration of additional securities for an S-1
4 May 23
CERT
Certification of approval for exchange listing
4 May 23
SEC STAFF
SEC staff action: Order
4 May 23
S-1/A
IPO registration (amended)
3 May 23
8-A12B
Registration of securities on exchange
2 May 23
CORRESP
Correspondence with SEC
2 May 23
CORRESP
Correspondence with SEC
2 May 23
S-1/A
IPO registration (amended)
1 May 23
CORRESP
Correspondence with SEC
20 Apr 23
S-1
IPO registration
13 Apr 23
CORRESP
Correspondence with SEC
13 Apr 23
UPLOAD
Letter from SEC
6 Apr 23
SEC STAFF
SEC staff action: Order
3 Apr 23
DRS/A
Draft registration statement (amended)
24 Mar 23
DRSLTR
Correspondence regarding draft registration statement
24 Mar 23
Latest ownership filings
SC 13G
INTEGRATED CORE STRATEGIES (US) LLC
20 May 24
4
Melanie Gloria
17 May 24
4
Mina Kim
17 May 24
4
Sanam Pangali
17 May 24
3
Shephard Mpofu
17 May 24
3
Sanam Pangali
17 May 24
SC 13G
INTEGRATED CORE STRATEGIES (US) LLC
19 Apr 24
4
Shao-Lee Lin
3 Apr 24
SC 13G
AyurMaya Capital Management Company, LP
28 Mar 24
144
Notice of proposed sale of securities
20 Mar 24
4
Shao-Lee Lin
22 Feb 24
SC 13G/A
CITADEL ADVISORS LLC
14 Feb 24
SC 13G
VANGUARD GROUP INC
13 Feb 24
SC 13G/A
FMR LLC
9 Feb 24
4
Shao-Lee Lin
11 Jan 24
4
Ronald Oyston
11 Jan 24
4
Mina Kim
11 Jan 24
4
Melanie Gloria
11 Jan 24
4
Gil M Labrucherie
11 Jan 24
4
Shao-Lee Lin
4 Jan 24
4
LYNN A. TETRAULT
20 Dec 23
3
LYNN A. TETRAULT
20 Dec 23
SC 13G
FMR LLC
13 Oct 23
SC 13G
FIL Ltd
10 Oct 23
4
Patrick Machado
6 Oct 23
4
Shao-Lee Lin
6 Oct 23
4
Paul Peloso
6 Oct 23
4
Gil M Labrucherie
6 Oct 23
4
Gil M Labrucherie
21 Aug 23
4
Ronald Oyston
18 Aug 23
4
Paul Peloso
18 Aug 23
4
Mina Kim
18 Aug 23
4
Melanie Gloria
18 Aug 23
4
Shao-Lee Lin
18 Aug 23
3
Gil M Labrucherie
3 Aug 23
SC 13G
CITADEL ADVISORS LLC
19 May 23
SC 13D
AI ACEL LLC
19 May 23
SC 13D
Westlake BioPartners Fund II, L.P.
19 May 23
4
Sean E Harper
11 May 23
4
BETH C SEIDENBERG
11 May 23